PBA
FULC icon

Paradigm Biocapital Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Paradigm Biocapital Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-212,961
Closed -$5.04M – 24
2022
Q1 		$5.04M Buy
+212,961
New +$3.01M 1.33% 23

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paradigm Biocapital Advisors's FULC Position: Q2 2022 in Review

Paradigm Biocapital Advisors sold out of Fulcrum Therapeutics (FULC) in Q2 2022, closing a stake of 212,961 shares — an estimated $5.04M sold.

Paradigm Biocapital Advisors first reported a position in FULC in Q1 2022 and held it in 1 quarter. The position peaked at $5.04M in Q1 2022. 101 funds tracked by Wall St. Rank hold FULC as of Q2 2022.

  • Paradigm Biocapital Advisors reported no remaining Fulcrum Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 212,961 Fulcrum Therapeutics shares in Q2 2022, an estimated $5.04M.
  • Paradigm Biocapital Advisors first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Fulcrum Therapeutics position peaked at $5.04M in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.